Vivus (VVUS) Sees Vibrant Trading on Qsymia Results

| January 7, 2013 | 0 Comments More

Vivus Pharmaceuticals (VVUS) adds $1.69 to $15.44 in early trading after reporting Qsymia 12,978 prescriptions shipped for four-weeks ended December 21, from 7,749 on November 23. The stock was also added to US 1 List at BofA/Merrill. Morning options trades on the stock include a sweep of 1,953 Jan 15 calls across multiple exchanges for 86 cents when the market was 79 to 85 cents. Stock was trading for slightly less than $15 at the time. 2,900 now traded against 5,734 in open interest and the market is 97c to $1.

Tags: ,

Category: All Stocks, Pharmaceuticals & Biotechnology, Small Cap Stocks

Please share if others would benefit

Leave a Reply

About the Author (Author Profile)

Frederic Ruffy is a well-known trader, writer, and strategist who has spent years educating investors and creating intelligent, insightful, unbiased market observations that are frequently cited by the Wall Street Journal and other financial publications. As senior analyst, Fred provides frequent and regular notes and daily updates for activity of interest.